GOVX GeoVax Labs, Inc.

-

GeoVax Labs Beat Consensus Estimates

Thursday, November 12, 2026 · 12:00 AM ET

GeoVax Labs (GOVX) reported a loss of $10.56 per share on revenue of $0.00 million for the third quarter ended September 2026. The consensus estimate was a loss of $24.58 per share. The company beat consensus estimates by 57.04%.

GeoVax Labs, Inc., is a development stage biotechnology company. It is engaged in developing human vaccines for diseases caused by Human Immunodeficiency Virus (HIV).

Earnings Whisper Grade —
Power Rating—
Reported Earnings
($10.56)
Earnings Whisper®
—
Consensus Estimate
($24.58)
Earnings Surprise
Earnings Growth-41.9 %
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth—